Innovation Meets Precision

• Fully automated
• Throughout of up to 2,640 test results per hour
• Simultaneous detection of up to 44 targets from a single patient sample.
• 1.8m (H) x 0.8m (D) x 1.3m (W)

A maximum throughput of up to 60 samples can be loaded per hour, providing up to 2,640 test results per hour / 19,580 test results per day. Software intuitively analyses what tests are being run and assigns the order of samples in the most time-efficient way for analysing and reporting results. The time to first sample results is just 36 minutes, with up to 44 results per sample. Results for remaining samples are released 1 sample per minute onward.

The RABTA consolidates theworkflow of multiple laboratories into a single analyser. The workload of laboratory staff is minimised, as only consumables and samples need to be loaded, and tests are selected via onscreen software.

Software allows users to assign samples as a priority over others so that priority samples can be run and results reported rapidly, eliminating the constraints of batch testing.

Continuous access to samples. Software-controlled access to reagents, biochips, signal and waste. The system can hold up to 60 samples with continuous access, and 120 biochips with software-controlled access.

Adaptable, Efficient & Comprehensive

• Semi-automated benchtop immunoanalyser
• Throughput of up to 2376 tests per hour
• Up to 44 simultaneous tests per sample
• 0.75m (H) x 0.48m (D) x 0.42m (W)

The Evidence Investigator is extremely well equipped to provide reliable results and robust enough to withstand frequent, heavy use. With only one moving part, the Investigator is extremely dependable and less susceptible to break downs.

The Evidence Investigator is the world’s first platform allowing consolidation of immunoassay and molecular diagnostics. This is achieved through utilising protein and DNA based biochips. By giving the user the ability to consolidate tests, the Evidence Investigator improves laboratory efficiency and reduces costs.

Biochip Array Technology enables the simultaneous/multiplex detection of a wide range of analytes from a single patient sample ultimately producing a complete patient profile for more informed diagnosis. Additional benefits include:

• Excellent correlation to gold standard methods
• Reduced costs and time owing to the multiplex nature of the method
• Small sample volume
• Multiple sample matrices

Revolutionary Biochip Array Technology from Randox does not employ the biotin-streptavidin method, increasing confidence in your laboratory’s immunoassay test results.

Fast. Fully Automated. Versatile

• Fully automated
• Throughout of up to 132 tests per hour
• Up to 44 simultaneous tests per sample
• 0.59m (H) x 0.54m (D) x 0.57m (W)

The process from sample entry to results can be completed in 3 simple steps, with minimum room for human error. MultiSTAT cartridges also come pre-filled with reagents. The process is designed to make set up and analysis as quick, simple and reliable as possible.

The Evidence MultiSTAT offers a complete drug screening solution to those who have no knowledge of laboratory procedures. Combining simplicity with cutting-edge innovation, the Evidence MultiSTAT makes laboratory quality results accessible to everyone, regardless of previous experience or location.

The Evidence MultiSTAT offers a complete drug screening solution to those who have no knowledge of laboratory procedures. Combining simplicity with cutting-edge innovation, the Evidence MultiSTAT makes laboratory quality results accessible to everyone, regardless of previous experience or location.

Biochip Array Technology enables the simultaneous/multiplex detection of a wide range of analytes from a single patient sample ultimately producing a complete patient profile for more informed diagnosis. Additional benefits include:

• Excellent correlation to gold standard methods
• Reduced costs and time owing to the multiplex nature of the method
• Small sample volume
• Multiple sample matrices

Revolutionary Biochip Array Technology from Randox does not employ the biotin-streptavidin method, increasing confidence in your laboratory’s immunoassay test results.

Randox has built a reputation in the development of protein-based immuno-assays, successfully addressing challenging requests, such as high sensitivity or exquisite selectivity in multiplex panels. With a test menu of over 400 immuno-assays available, in a variety of assay formats and adaptable to most automated analysers on the market-place, we strive to increase our test menu every year. Starting with innovative Immunogen generation, active Ab clone characterization and selection, and final assay delivery to fit-for-purpose validation standards, from RUO to IVD reagents.

The Precision Medicine concept has significantly changed the way drug development is being handled and companion diagnostics have come to the forefront of medical innovation, by enabling targeted treatments in a variety of therapeutic areas. Assay development skills, Market access capabilities and Regulatory competencies are the key elements to bring a drug-tailored assay to life, built to Sponsor’s specifications and delivered on time to support the successful release of the newly approved drug. With a long-recognized expertise in the development of esoteric assays, and more than 500 IVD products available globally, Randox is a partner of choice to support your CDx needs, primarily but not only in the field of Immuno-assays.